非布司他价格

Price: The price of the original medicine of Febuxostat in Japan is relatively high, about 1500$ per box. Febuxostat produced by Zydus Pharmaceuticals in India has the same efficacy as the original drug. The specification is 80mg*30 tablets/box, and its price is about $200.

Febuxostat is a new anti-hyperuricemia drug developed by Teijin Pharma in Tokyo, Japan. It applied for marketing in Japan in early 2004. In April 2008, the European Union first approved the marketing of febuxostat tablets, with specifications of 80 mg and 120 mg, and the trade name "Adenuric". It is used to treat chronic hyperuricemia with uric acid deposition (including patients with gout stones and/or gouty arthritis, or patients with a history of this). In February 2009, the FDA approved the marketing of febuxostat tablets in specifications of 40 mg and 80 mg, with the trade name "ULORIC", for the long-term control of hyperuricemia in patients with gout.

Clinical experiments show that compared with the traditional treatment drug allopurinol, febuxostat is more effective in reducing uric acid. The most common adverse reactions are abnormal liver function, diarrhea and rash. Medication guidelines recommend a starting dose of 40 mg/d. In patients with mild to moderate renal impairment (creatinine clearance [CrCl] 30-89 mL/min), the starting dose is the same as in patients with normal renal function.

Among the current clinical drugs for the treatment of gout (uric acid-lowering), there are mainly three types of drugs: allopurinol, febuxostat, and benzbromarone. Tests have shown that compared with benzbromarone, allopurinol and febuxostat have no risk of uric acid kidney stones; compared with allopurinol and febuxostat, the biggest advantage of benzbromarone is that it does not cause dryness. Interfering with cell metabolism; compared with benzbromarone and allopurinol, febuxostat has a smaller risk of kidney damage; compared with allopurinol, febuxostat and benzbromarone have a smaller risk of drug rash or hypersensitivity reactions, but in addition to reducing acidity, allopurinol can also inhibit the production of new purines and improve the function of vascular endothelium. Febuxostat is a newly developed drug, and at the same dose, febuxostat has a stronger effect in reducing blood uric acid. Therefore, when it comes to the choice of acid-lowering drugs for gout, many patients prefer febuxostat.

For more information, patients can consult Medical Companion Travel.